Of note, levels of decisional conflict in the PRIMETIME SWAT are similar to those in the IBIS II trial which investigated the use of a PDA in a randomised controlled trial of an aromatase inhibitor in patients at high risk of breast cancer (prevention group) and patients with DCIS (treatment group) [13.2 (SD = 14.5)] [14]. This evidence concerns the gene CYP19A1 and ductal breast carcinoma in situ.